EGFR and breast carcinoma: To investigate whether E1A would enhance the sensitization to EGFR-TKI in breast cancer cells, we examined the sensitivity to lapatinib, gefitinib or erlotinib in MDA-MB-231 and HBL100 cells with ectopic expression of E1A.